Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRSD107
- Development stage
- Phase 2
- Lead developer
- Sirius Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SRSD107 is a novel, synthetic, chemically modified double-stranded small interfering ribonucleic acid (siRNA) therapy developed by Sirius Therapeutics. It specifically targets human coagulation factor XI (FXI) mRNA, inhibiting FXI protein expression and thereby blocking the intrinsic coagulation pathway. This mechanism promotes anticoagulant and anti-thrombotic effects with the aim of reducing thrombosis risk without significantly increasing bleeding risk. Preclinical studies demonstrated near-complete reduction of FXI levels for up to six months after a single subcutaneous dose, with no observed bleeding events. The drug is being developed for once or twice-a-year dosing to improve patient compliance in chronic anticoagulation settings. Phase 1 clinical trials have shown that SRSD107 is safe and well-tolerated in healthy subjects, with durable pharmacodynamic effects lasting over 16 weeks after dosing[1][2][3][5][6][7][8].
- Other names
- SRSD107SRSD-107SRSD 107
02
Targets
F11 (Coagulation Factor XI)
Beyond the preview
Go deeper on SRSD107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRSD107.